Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARCOME 09 OS2006 - Zoledronate Osteosarcoma
2024-514756-32-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of zoledronic acid in osteosarcoma (OS) (2 arms), sponsored by Unicancer. Primary endpoint: Event-free survival at 3 years. Planned start Aug 2024; status: authorised.
02
Drugs
zoledronic acid
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2024-514756-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514756-32-00.